Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report)’s share price traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.23. 15,196,699 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 60,758,266 shares. The stock had previously closed at $0.24.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Friday. They set a “hold” rating on the stock.
Get Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Stock Down 2.8 %
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Further Reading
- Five stocks we like better than Tonix Pharmaceuticals
- How to invest in marijuana stocks in 7 steps
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Differences Between Momentum Investing and Long Term Investing
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- When to Sell a Stock for Profit or Loss
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.